Moderna Stock Price, News & Analysis

Moderna (MRNA) announces that its COVID-19 vaccine, mRNA-1273, remains highly effective against the Delta variant. A study involving 352,878 vaccinated individuals indicated an effectiveness rate of 87% against COVID-19 diagnosis and 96% against hospitalization. An analysis of their Phase 3 COVE study revealed a 36% reduction in breakthrough infections for those vaccinated more recently compared to those vaccinated earlier. The company advocates for a booster dose to enhance immunity and will share findings in a conference call.

Moderna, Inc. (NASDAQ: MRNA) has made significant advancements in its mRNA vaccine pipeline, as announced during its fifth annual R&D Day. Key highlights include the development of a combination respiratory vaccine for COVID-19 and flu, and a pediatric vaccine for RSV and hMPV. Interim Phase 1 data showed boosted neutralizing antibody titers in older adults for the RSV candidate. Additionally, a personalized cancer vaccine trial is fully enrolled. Moderna currently has 37 programs in development, including 22 in clinical studies.

Moderna, Inc. (MRNA) has partnered with National Resilience, Inc. to manufacture mRNA for its COVID-19 vaccine. This multi-year agreement will utilize Resilience's facility in Mississauga, Ontario, ensuring global distribution of the vaccine. The collaboration aims to broaden access to Moderna's vaccines and enhance pandemic response capabilities. Additionally, Moderna has initiated a collaboration with Canada to establish a state-of-the-art mRNA manufacturing facility, further solidifying its commitment to expanding healthcare solutions against respiratory viruses.

National Resilience, Inc. and Moderna, Inc. have entered a multi-year agreement for the manufacturing of mRNA for the Moderna COVID-19 vaccine. The mRNA will be produced at Resilience's facility in Mississauga, Ontario, for global distribution. Resilience's CEO, Rahul Singhvi, highlighted the impact of Moderna’s vaccine in saving lives and expressed excitement about this partnership, which aims to enhance vaccination efforts worldwide.

Moderna has announced a collaboration with the Institute for Life Changing Medicines (ILCM) to develop an mRNA therapy, mRNA-3351, for Crigler-Najjar Syndrome Type 1 (CN-1), an ultra-rare genetic disorder affecting about 70-100 individuals globally. This partnership aims to provide the therapy free of charge to patients. Moderna will license mRNA-3351 to ILCM without upfront fees, and ILCM will handle clinical development, projected to start in 2022. This initiative reflects Moderna's commitment to addressing rare diseases without imposing high costs on patients.

Moderna, Inc. (Nasdaq: MRNA) has submitted a request for conditional marketing approval to the European Medicines Agency (EMA) for its COVID-19 vaccine booster dose, mRNA-1273, at a 50 µg level. The amended Phase 2 study involving 344 participants showed that this booster significantly increases antibody responses, particularly against the Delta variant, boosting neutralizing titers above Phase 3 benchmarks. The safety profile after the third dose was similar to that of the second dose, indicating the potential for effective ongoing immunity against COVID-19.

Moderna (NASDAQ: MRNA) announced participation in two virtual investor conferences on September 10, 2021. The Wells Fargo 2021 Virtual Healthcare Conference will begin at 10:00 a.m. ET, followed by the Morgan Stanley 19th Annual Global Healthcare Conference at 11:45 a.m. ET. Live webcasts can be accessed on the Moderna Investors website and will be available for replay for 30 days. Moderna has emerged as a leader in mRNA therapeutics, developing vaccines and treatments across various therapeutic areas.

Moderna (NASDAQ:MRNA) has submitted data to the FDA for a booster dose of its COVID-19 vaccine (mRNA-1273) at a 50 µg dose level. The submission is backed by Phase 2 study data showing significant antibody responses against the Delta variant, exceeding benchmarks. Following the booster, neutralizing antibody titers increased significantly, especially in older adults. The safety profile remained consistent with previous doses. Moderna plans to submit further data to the EMA and other global authorities soon.

Moderna has completed its Biologics License Application (BLA) for the COVID-19 vaccine, requesting Priority Review from the FDA. The final analysis of the Phase 3 COVE study shows the vaccine has a 93% efficacy rate, which remains durable for six months after the second dose. This marks the first BLA submission in Moderna's history. The company aims for full licensure to prevent COVID-19 in individuals aged 18 and older. The vaccine has been available under Emergency Use Authorization since December 2020 and has delivered over 300 million doses to the U.S. government.